A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid X receptor heterodimers

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 1, 2012, Pages 1-9

  Kotani, Hitoshi ^a,b   Tanabe, Hiroki ^a   Mizukami, Hajime ^b   Amagaya, Sakae ^c   Inoue, Makoto ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Honokiol; Liver X receptor; Peroxisome proliferator activated receptor; Retinoid X receptor agonist; Rexinoid; Vitamin D receptor

Indexed keywords

BEXAROTENE; CALCITRIOL; HONOKIOL; LIVER X RECEPTOR; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR; ROSIGLITAZONE; VITAMIN D RECEPTOR;

ANIMAL CELL; ARTICLE; CELL STRAIN 3T3; CELL STRAIN CACO 2; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3T3-L1 CELLS; ANIMALS; ANTICARCINOGENIC AGENTS; BIPHENYL COMPOUNDS; CACO-2 CELLS; DIMERIZATION; HUMANS; LIGNANS; MAGNOLIA; MICE; ORPHAN NUCLEAR RECEPTORS; PLANT EXTRACTS; PPAR GAMMA; RECEPTORS, CALCITRIOL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOID X RECEPTORS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES; THIAZOLIDINEDIONES;

EID: 84855657286     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.1     Document Type: Article

References (44)

1. Mangelsdorf DJ, Ong ES, Dyck JA, Evans RM. Nuclear receptor that identifies a novel retinoic acid response pathway. Nature, 345, 224-229 (1990).
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell, 83, 835-839 (1995).
3. Magelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, Kakizuka A, Evans RM. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev., 6, 329-344 (1992).
4. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell, 83, 841-850 (1995).
5. Forman BM, Umesono K, Chen J, Evans RM. Unique response pathways are established by allosteric interactions among nuclear hormone receptors. Cell, 81, 541-550 (1995).
6. Botling J, Castro DS, Öberg F, Nilsson K, Perlmann T. Retinoic acid receptor/retinoid X receptor heterodimers can be activated through both subunits providing a basis for synergistic transactivation and cellular differentiation. J. Biol. Chem., 272, 9443-9449 (1997).
7. Li D, Li T, Wang F, Tian H, Samuels HH. Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. Mol. Cell. Biol., 22, 5782-5792 (2002).
8. Bettoun DJ, Burris TP, Houck KA, Buck DW 2nd, Stayrook KR, Khalifa B, Lu J, Chin WW, Nagpal S. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol. Endocrinol., 17, 2320-2328 (2003).
9. Mukherjee R, Davies PJA, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature, 386, 407-410 (1997).
10. Lalloyer F, Fiévet C, Lestavel S, Torpier G, van der Veen J, Touche V, Bultel S, Yous S, Kuipers F, Paumelle R, Fruchart JC, Staels B, Tailleux A. The RXR agonist bexarotene improves cholesterol homeostasis and inhibits atherosclerosis progression in a mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol., 26, 2731-2737 (2006).
11. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, Speck J, Kratzeisen C, Rosenberger M, Lovey A, Grippo JF. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature, 355, 359-361 (1992).
12. de Urquiza AM, Liu S, Sjöberg M, Zetterström RH, Griffiths W, Sjövall J, Perlmann T. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science, 290, 2140-2144 (2000).
13. Kitareewan S, Burka LT, Tomer KB, Parker CE, Deterding LJ, Stevens RD, Forman BM, Mais DE, Heyman RA, McMorris T, Weinberger C. Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR. Mol. Biol. Cell, 7, 1153-1166 (1996).
14. Pinaire JA, Reifel-Miller A. Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome. PPAR Res., 2007, 94156 (2007).
15. Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD. Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat. Endocrinology, 143, 2880-2885 (2002).
16. Lenhard JM, Lancaster ME, Paulik MA, Weiel JE, Binz JG, Sundseth SS, Gaskill BA, Lightfoot RM, Brown HR. The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction. Diabetologia, 42, 545-554 (1999).
17. Kotani H, Tanabe H, Mizukami H, Makishima M, Inoue M. Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J. Nat. Prod., 73, 1332-1336 (2010).
18. Jung CG, Horike H, Cha BY, Uhm KO, Yamauchi R, Yamaguchi T, Hosono T, Iida K, Woo JT, Michikawa M. Honokiol increases ABCA1 expression level by activating retinoid X receptor beta. Biol. Pharm. Bull., 33, 1105-1111 (2010).
19. Széles L, Póliska S, Nagy G, Szatmari I, Szanto A, Pap A, Lindstedt M, Santegoets SJAM, Rühl R, Dezsö B, Nagy L. Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol. Endocrinol., 24, 2218-2231 (2010).
20. Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira K, Sai K, Kagechika H, Shudo K, Abe-Dohmae S, Yokoyama S, Ohno Y, Inoue K, Sawada J. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines. Biochem. Pharmacol., 76, 1006-1013 (2008).
21. Stenson BM, Rydén M, Steffensen KR, Wåhlén K, Pettersson AT, Jocken JW, Arner P, Laurencikiene J. Activation of liver X receptor regulates substrate oxidation in white adipocytes. Endocrinology, 150, 4104-4113 (2009).
22. Stenson BM, Rydén M, Venteclef N, Dahlman I, Pettersson AML, Mairal A, Aström G, Blomqvist L, Wang V, Jocken JWE, Clément K, Langin D, Arner P, Laurencikiene J. Liver X receptor (LXR) regulates human adipocyte lipolysis. J. Biol. Chem., 286, 370-379 (2011).
23. Choi SS, Cha BY, Iida K, Sato M, Lee YS, Teruya T, Yonezawa T, Nagai K, Woo JT. Honokiol enhances adipocyte differentiation by potentiating insulin signaling in 3T3-L1 preadipocytes. J. Nat. Med., 65, 424-430 (2011).
24. Alonso-Castro AJ, Zapata-Bustos R, Domínguez F, García-Carrancá A, Salazar-Olivo LA. Magnolia dealbata Zucc and its active principles honokiol and magnolol stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway. Phytomedicine, 18, 926-933 (2011).
25. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim. Biophys. Acta, 1814, 186-199 (2011).
26. Holick MF. Vitamin D and bone health. J. Nutr., 126 (Suppl.), 1159S-1164S (1996).
27. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat. Rev. Immunol., 8, 685-698 (2008).
28. Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, Su SB, Chan CC, Adorini L, Caspi RR. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. J. Immunol., 182, 4624-4632 (2009).
29. Shen Q, Cline GW, Shulman GI, Leibowitz MD, Davies PJA. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (db/db) mice. J. Biol. Chem., 279, 19721-19731 (2004).
30. Claudel T, Leibowitz MD, Fiévet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. U.S.A., 98, 2610-2615 (2001).
31. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta, 1771, 1065-1081 (2007).
32. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DLA. A Phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy. Clin. Cancer Res., 5, 1339-1345 (1999).
33. Konoshima T, Kozuka M, Tokuda H, Nishino H, Iwashima A, Haruna M, Ito K, Tanabe M. Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis. J. Nat. Prod., 54, 816-822 (1991).
34. Munroe ME, Arbiser JL, Bishop GA. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J. Immunol., 179, 753-763 (2007).
35. Kim BH, Cho JY. Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression. Acta Pharmacol. Sin., 29, 113-122 (2008).
36. Tsai SK, Huang CH, Huang SS, Hung LM, Hong CY. Antiarrhythmic effect of magnolol and honokiol during acute phase of coronary occlusion in anesthetized rats: influence of L-NAME and aspirin. Pharmacology, 59, 227-233 (1999).
37. Maruyama Y, Kuribara H, Morita M, Yuzurihara M, Weintraub ST. Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine. J. Nat. Prod., 61, 135-138 (1998).
38. Hu H, Zhang XX, Wang YY, Chen SZ. Honokiol inhibits arterial thrombosis through endothelial cell protection and stimulation of prostacyclin. Acta Pharmacol. Sin., 26, 1063-1068 (2005).
39. Han SJ, Bae EA, Trinh HT, Yang JH, Youn UJ, Bae KH, Kim DH. Magnolol and honokiol: inhibitors against mouse passive cutaneous anaphylaxis reaction and scratching behaviors. Biol. Pharm. Bull., 30, 2201-2203 (2007).
40. Ai J, Wang X, Nielsen M. Honokiol and magnolol selectively interact with GABAA receptor subtypes in vitro. Pharmacology, 63, 34-41 (2001).
41. Squires RF, Ai J, Witt MR, Kahnberg P, Saederup E, Sterner O, Nielsen M. Honokiol and magnolol increase the number of [3H] muscimol binding sites three-fold in rat forebrain membranes in vitro using a filtration assay, by allosterically increasing the affinities of low-affinity sites. Neurochem. Res., 24, 1593-1602 (1999).
42. Munroe ME, Businga TR, Kline JN, Bishop GA. Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma. J. Immunol., 185, 5586-5597 (2010).
43. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J. Immunol., 173, 5298-5304 (2004).
44. Lee HC, Headley MB, Iseki M, Ikuta K, Ziegler SF. Cutting edge: Inhibition of NF-kappaB-mediated TSLP expression by retinoid X receptor. J. Immunol., 181, 5189-5193 (2008).